TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
61.85
-0.90 (-1.43%)
At close: 4:00PM EDT

62.27 +0.42 (0.68%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close62.75
Open62.81
Bid61.99 x 1200
Ask64.49 x 800
Day's Range61.15 - 64.84
52 Week Range31.30 - 72.03
Volume284,349
Avg. Volume385,124
Market Cap2.557B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.70
Earnings DateAug 06, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Turning Point Therapeutics Licenses Its Lung Cancer Drug in China
    Motley Fool

    Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

    Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.

  • GlobeNewswire

    Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (ZLAB), an innovative commercial-stage biopharmaceutical company, today announced an exclusive license agreement for the development and commercialization of Turning Point’s lead drug candidate, repotrectinib, in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments.

  • GlobeNewswire

    Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

    SAN DIEGO, June 22, 2020 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of.

  • GlobeNewswire

    Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate via webcast in a question and answer session at the 41st annual Goldman Sachs Global Healthcare Conference on June 9. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

    SAN DIEGO, May 29, 2020 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of.

  • Trade Alert: The President Of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), Athena Countouriotis, Has Just Spent US$250k Buying 18% More Shares
    Simply Wall St.

    Trade Alert: The President Of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), Athena Countouriotis, Has Just Spent US$250k Buying 18% More Shares

    Investors who take an interest in Turning Point Therapeutics, Inc. (NASDAQ:TPTX) should definitely note that the...

  • GlobeNewswire

    Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offering of its common stock have exercised in full their option to purchase 812,500 additional shares of common stock at the public offering price of $60.00 per share. The initial sale of 5,416,667 shares of common stock was completed on May 21, 2020 and the sale of the additional 812,500 shares is expected to close on or about May 28, 2020, subject to satisfaction of customary closing conditions. Goldman Sachs & Co. LLC, SVB Leerink and Guggenheim Securities are acting as joint bookrunning managers for the offering.

  • GlobeNewswire

    Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416,667 shares of its common stock at a price to the public of $60.00 per share. In addition, Turning Point has granted the underwriters a 30-day option to purchase up to an additional 812,500 shares of common stock. Goldman Sachs & Co. LLC, SVB Leerink and Guggenheim Securities are acting as joint bookrunning managers for the offering.

  • GlobeNewswire

    Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $250,000,000 of shares of its common stock. In connection with the offering, Turning Point expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Turning Point Therapeutics Inc (TPTX) Q1 2020 Earnings Call Transcript
    Motley Fool

    Turning Point Therapeutics Inc (TPTX) Q1 2020 Earnings Call Transcript

    Leading the call today will be Turning Point's President and Chief Executive Officer, Dr. Athena Countouriotis, who will provide an overview and update on our business results including our response to the COVID-19 pandemic. Athena's remarks will be followed by a review of our financials by our CFO, Yi Larson. Before Athena begins, I want to remind you that during this conference call, we will be making forward-looking statements.

  • GlobeNewswire

    Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

    Repotrectinib Granted Fast Track Designation in ROS1-Positive Advanced Non-Small Cell Lung Cancer Patients Not Previously Treated with a ROS1 Tyrosine Kinase Inhibitor  First.

  • Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX
    Zacks

    Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX

    Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.

  • GlobeNewswire

    Turning Point Therapeutics to Host First Quarter Conference Call

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report first quarter financial results following the close of U.S. financial markets on May 12 and host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment-Naïve and Solvent-Front Mutation Ros1-Positive Non-Small Cell Lung Cancer

    SAN DIEGO, April 16, 2020 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of.

  • Turning Point Therapeutics (NASDAQ:TPTX) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Turning Point Therapeutics (NASDAQ:TPTX) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • ACCESSWIRE

    Turning Point Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Turning Point Therapeutics, Inc. (NASDQ:TPTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 ...

  • GlobeNewswire

    TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS

    Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131.

  • GlobeNewswire

    Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and 2019 financial results following the close of U.S. financial markets on Mar. 18 and host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and chief scientific officer effective March 2. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer. Dr. Reich was most recently senior vice president of research and co-founder of eFFECTOR Therapeutics where he led discovery of three first-in-class small-molecule inhibitors, of MNK (tomivosertib), eIF4A (zotatifin), and eukaryotic initiation factor 4E (eIF4E).

  • GlobeNewswire

    Turning Point Therapeutics to Participate in Upcoming Investor Conferences

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics to Participate in Guggenheim Oncology Day

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Guggenheim Healthcare Talks Oncology Day in New York on Feb. 13. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise. “Garry brings deep expertise in oncology commercial strategy to the board at an important time for the company as we prepare for the potential commercialization of our lead asset,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

  • GlobeNewswire

    Turning Point Therapeutics Announces Program Updates and Milestones for 2020

    Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...